Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes

Takehiro Kanamori,¹ Yumie Takeshita,¹ Yuki Isobe,¹ Ken-ichiro Kato,¹ Hirofumi Misu,¹ Shuichi Kaneko,² Toshinari Takamura¹

To cite: Kanamori T, Takeshita Y, Isobe Y, *et al*. Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes. *BMJ Open Diab Res Care* 2018;**6**:e000588. doi:10.1136/bmjdr-2018-000588

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2018-000588>).

For Presented at statement see end of article.

Received 30 July 2018
Revised 18 September 2018
Accepted 6 October 2018

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Toshinari Takamura;
ttakamura@m-kanazawa.jp

ABSTRACT

Objective Glucose variability induces endothelial dysfunction and cardiac autonomic nerve abnormality. Here we compared the effects of mealtime insulin aspart and bedtime insulin detemir on glucose variability, endothelial function, and cardiac autonomic nerve activity among Japanese patients with type 2 diabetes.

Research design and methods Forty hospitalized patients received either mealtime insulin aspart or bedtime insulin detemir treatment for 2 weeks. We assessed glucose variability indices, including M-value, SD of blood glucose level, and mean blood glucose (MBG) level. Flow-mediated dilation (FMD) of the brachial artery was measured as an index of endothelial function. Low-frequency power, high-frequency power, and the low-frequency to high-frequency power ratio (LF:HF ratio) derived via heart rate variability analysis using a Holter ECG were employed as indices of cardiac autonomic nerve function.

Results M-values and MBG levels showed a considerably greater decrease in the insulin aspart group than in the insulin detemir group ($p=0.006$ vs $p=0.001$); no change in FMD was observed in either group. Daytime LF:HF ratio significantly decreased in the insulin aspart group but not in the insulin detemir group. Total insulin dose at endpoint in the insulin aspart group was significantly higher than that in the insulin detemir group ($p<0.001$).

Conclusions Mealtime insulin aspart reduced glucose variability to a greater extent than bedtime insulin detemir in patients with type 2 diabetes. Despite the need for higher insulin doses, insulin aspart decreased daytime cardiac sympathetic nerve activity. These properties may subsequently help reduce cardiovascular risks.

Trial registration number UMIN000008369.

INTRODUCTION

Type 2 diabetes is a progressive disease, and a considerable proportion of patients eventually

Significance of this study

What is already known about this subject?

- Glucose variability, cardiac sympathetic nerve activity, and endothelial function are widely accepted as surrogate markers of cardiovascular disease.
- The effects of rapid-acting insulin analog or long-acting insulin analog on glucose variability, cardiac sympathetic nerve activity, and endothelial function have not been studied.

What are the new findings?

- Mealtime insulin aspart treatment profoundly improved glucose variability, particularly by reducing postprandial glucose levels, compared with bedtime insulin detemir treatment.
- Despite the larger daily total insulin dose, mealtime insulin aspart treatment suppressed daytime cardiac sympathetic nerve activity compared with bedtime insulin detemir treatment.

How might these results change the focus of research or clinical practice?

- The present study highlights the previously under-recognized effects of mealtime rapid-acting insulin dosing on glucose variability and cardiac sympathetic nerve activity.
- Longitudinal studies are needed to determine whether the appropriate use of rapid-acting insulin analog may help reduce cardiovascular events.

require insulin therapy. Long-acting insulin analog treatment is recommended for patients who fail to achieve glycemic control with oral antidiabetic agents.¹ Data pertaining to the effects of long-acting and rapid-acting insulin analogs on glucose profile in Caucasian

patients with type 2 diabetes are widely available.^{2,3} Long-acting insulin analog treatment is widely accepted owing to its ease of handling, low risk for hypoglycemia and body weight gain, and slightly inferior or equal hemoglobin A1c-lowering effects compared with rapid-acting insulin analog treatment.

In contrast, the clinical features of East Asian patients with type 2 diabetes are different from those of Caucasians; for example, East Asians with type 2 diabetes tend to show lower insulin resistance compared with Caucasians.⁴ This suggests that East Asians with type 2 diabetes may require less long-acting insulin analogs to suppress liver gluconeogenesis. Moreover, in our previous study of Japanese patients with type 2 diabetes, approximately half (52.5%) of those with hemoglobin A1c >8.4% achieved adequate fasting glucose levels (<120 mg/dL) through mealtime dosing of a rapid-acting insulin analog.⁵ These observations indicate that treatment with rapid-acting insulin analogs may perhaps efficiently improve postprandial and fasting hyperglycemia in East Asians with type 2 diabetes. Furthermore, given that glucose variability associated with postprandial hyperglycemia induces cardiac sympathetic nerve overactivity and endothelial dysfunction,^{6,7} glucose variability is widely accepted as a therapeutic target for prevention of cardiovascular diseases.

The present study aimed to compare the effects of mealtime rapid-acting insulin analog treatment and bedtime long-acting insulin analog treatment on glucose variability, endothelial function, and cardiac autonomic nerve function among Japanese patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS

Patients

A total of 40 patients admitted to Kanazawa University Hospital between August 2010 and July 2012 were enrolled. The eligibility criteria were patients with type 2 diabetes aged ≥20 years with hemoglobin A1c ≥7.4%. The diagnosis of type 2 diabetes was based on the 2010 Japan Diabetes Society criteria.⁸ The exclusion criteria were as follows: (1) hypersensitivity or contraindication to insulin aspart or detemir; (2) present or history of diabetic ketoacidosis; (3) present or history of severe hypoglycemia; (4) severe infection or severe trauma presurgery/postsurgery; (5) treatment with insulin, dipeptidyl peptidase-4 inhibitor, or glucagon-like peptide-1 receptor agonist in the 4 weeks immediately preceding the study; (6) glucocorticoid treatment; (7) poorly controlled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg); (8) severe retinopathy; (9) significant medical history and/or malignancy; (10) severe complications and conditions not suitable for the study (hyperosmolar hyperglycemic state or heart failure); and (11) pregnant or lactating women. The study is registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (trial registration number UMIN000008369).

Procedures

Using a computer-generated sequence, patients were randomly assigned to receive either insulin aspart (Novo Nordisk A/S, Bagsvaerd, Denmark) thrice daily before meals or insulin detemir (Novo Nordisk A/S) once daily at bedtime. Sulfonylureas and glinides were discontinued after treatment assignment, whereas other hypoglycemic agents remained unchanged.

Insulin therapy was initiated after an initial assessment. Physicians performed daily insulin dose titrations to achieve the glycemic goal. In the insulin aspart group, target prandial blood glucose levels were 70–110 mg/dL, whereas target postprandial (2 hours after a meal) blood glucose levels were 70–140 mg/dL. The target fasting blood glucose levels were between 80 and 110 mg/dL in the insulin detemir group. Blood glucose levels were measured using a blood glucometer (Glutest Neo Super, Sanwa Kagaku Kenkyusho, Aichi, Japan) at seven different time points: prebreakfast, postbreakfast, prelunch, postlunch, predinner, postdinner, and at bedtime (ie, at 07:00, 09:00, 12:00, 14:00, 18:00, 20:00, and 22:00, respectively). Patients were placed on a regular hospital diet (30 kcal/kg ideal body weight comprising 50%–60% carbohydrate, 20%–30% fat, and 15%–20% protein).

Assessments

The primary endpoint was change in glucose variability indices from baseline until week 2. Glucose variability indices included the M-value, SD of blood glucose level, and mean blood glucose (MBG) level, all of which were obtained from the seven-point blood glucose profiles. The M-value was calculated using the following formula^{9,10}:

$$M - \text{value} = \frac{\sum M_{BG}}{7} + M_W$$

$$M_{BG} = 110 \log \frac{BG_t}{100}^3$$

$$M_W = \frac{G_{\max} - G_{\min}}{20}$$

where BG_t is the blood glucose level at each time point; $G_{\max}$ is the maximum blood glucose level throughout the day; and $G_{\min}$ is the minimum blood glucose level throughout the day.

Endothelial function and cardiac sympathetic nerve function were assessed as surrogate markers of cardiovascular disease at baseline and after 2 weeks of treatment. Moreover, body mass index, white cell count, liver function tests, lipid profile, respiratory quotient, basal metabolic rate, treatment safety, and total insulin dose were also assessed. Homeostatic model assessment of insulin resistance (HOMA-IR) and β -cell function (HOMA- β) were calculated as follows: HOMA-IR = fasting plasma insulin $\times$ fasting plasma glucose / 405; HOMA- β = fasting plasma insulin $\times$ 360 / (fasting plasma glucose – 63).¹¹

Diabetic microvascular complications were evaluated at baseline. Diabetic retinopathy was diagnosed using fundus ophthalmoscopy by ophthalmologists. Diabetic nephropathy was assessed by measurement of the urinary albumin to creatinine ratio in a spot urine sample. Diabetic autonomic neuropathy was assessed by measurement of the

coefficient of variation for R-R interval at rest (CVR-R) on ECG. CVR-R of 2% was considered a critical level for diabetic autonomic neuropathy.¹²

Flow-mediated dilation of the brachial artery

Flow-mediated dilation (FMD) of the brachial artery was assessed with reference to guidelines.^{13 14} Patients were asked to rest in a supine position for at least 10 min. The brachial artery diameter of their right arm was measured by a single sonographer using a Doppler ultrasound system. A blood pressure cuff was inflated around the right forearm to occlude the brachial artery for 5 min. The brachial artery diameter was measured again at 1 min after releasing the cuff. FMD of the brachial artery was calculated as the percentage change in the diameter from baseline to that at 1 min after cuff deflation. The examination was performed mainly between 16:00 and 18:00, before dinner.

Cardiac autonomic nerve activity

Cardiac autonomic nerve activity was assessed by spectral analysis of heart rate variability. The present study employed 24-hour Holter electrocardiographic monitoring while also analyzing the frequency domain measures of heart rate variability using the MemCalc/Chiram3 software (GMS Company, Tokyo, Japan). Low-frequency (LF; 0.04–0.15 Hz) power, high-frequency (HF; 0.15–0.40 Hz) power, as well as the low-frequency to high-frequency power ratio (LF:HF ratio) were calculated at 5 min intervals while averaging each component on an hourly or daily basis. LF power, HF power, and LF:HF ratio are known to reflect sympathetic nerve activity, vagal nerve activity, and the sympathovagal balance, respectively.¹⁵

Respiratory quotient and basal energy expenditure

Whole-body oxygen consumption (VO_2) and carbon dioxide production (VCO_2) were measured during the prebreakfast period (between 06:30 and 07:00) with indirect calorimetry using a Minato AE-310s Aeromonitor (Minato Medical Science Company, Osaka, Japan). Respiratory quotient was defined as the ratio of VCO_2 to VO_2 . Basal energy expenditure was calculated from VO_2 and VCO_2 using the Weir equation.¹⁶

Statistical analyses

All variables are expressed as mean and SD. Measures of heart rate variability were natural log-transformed to adjust for skewed distribution. Paired t-test or Wilcoxon's signed-rank test was performed to assess the intra-group differences from baseline. Analysis of covariance with baseline variables as covariates was used to compare changes in variables from baseline. Pearson correlation analysis was used to explore associations between variables. All analyses were performed on the full analysis set. Data were analyzed using the IBM SPSS Statistics V.20.0 software. A two-tailed p value <0.05 was considered statistically significant.

RESULTS

Patient characteristics

Eighteen and 20 patients in the insulin aspart and insulin detemir groups, respectively, were included in the analysis. One patient in the insulin aspart group withdrew consent after assignment, while another dropped out of the study owing to protocol violation (online supplementary figure 1). Baseline characteristics did not significantly differ between the two groups (table 1). Approximately half of the patients in both groups showed CVR-R of less than 2%, which is suggestive of diabetic autonomic neuropathy. Sulfonylureas were administered in two and five patients in the insulin aspart and insulin detemir groups, respectively. In these patients, insulin treatment was started at least 3 days after cessation of sulfonylurea therapy.

Glucose variability

Blood glucose profiles at baseline were similar in both groups (figure 1A,B). A significant decrease in blood glucose levels at all time points was observed in both groups after 2 weeks of treatment. Postlunch, postdinner, and bedtime blood glucose levels at endpoint were markedly lower in the insulin aspart group than in the insulin detemir group (figure 1C). Nadir fasting blood glucose levels with mealtime dosing of insulin aspart and bedtime dosing of insulin detemir were roughly similar (121.8 ± 23.6 mg/dL vs 106.2 ± 22.9 mg/dL; $p=0.063$). M-values and MBG levels in the insulin aspart group were considerably lower than those in the insulin detemir group (table 1). A similar reduction in the SD of blood glucose levels was observed in both groups.

Endothelial function

FMD of the brachial artery was assessed in 14 and 15 patients in the insulin aspart and insulin detemir groups, respectively. No significant change in FMD was observed in either of the groups after 2 weeks of treatment (table 1 and online supplementary figure 2). Changes in FMD during the 2-week treatment period did not correlate with changes in M-values, MBG levels, and the SD of blood glucose levels (data not shown).

Cardiac autonomic nerve function

Cardiac autonomic nerve function was assessed in 13 patients each in the insulin aspart and insulin detemir groups. After 2 weeks of treatment, the 24-hour LF and HF power decreased, whereas the 24-hour LF:HF ratio remained unchanged in both groups (table 1). Careful observation of each time point (figure 2) revealed a significant decrease in the daytime LF:HF ratio in the insulin aspart group (figure 2E) but not in the insulin detemir group (figure 2F). At endpoint, the HF power from 12:00 to 13:00 in the insulin aspart group was significantly higher than that in the insulin detemir group (online supplementary figure 3). Consistent with this finding, the LF:HF ratio from 12:00 to 13:00 in the insulin aspart group was considerably lower than that in the insulin detemir group.

Table 1 Patient characteristics at baseline and after 2 weeks of treatment

Variable	Insulin aspart			Insulin detemir					
	n	Baseline	Endpoint	P values*	n	Baseline	Endpoint	P values*	P value†
Male/Female (n)	18	12/6			20	16/4			
Age (years)	18	59.1±17.7			20	56.9±13.9			
Duration (years)	18	6.1±6.6			20	6.2±10.1			
Retinopathy (n)	18	4			20	4			
Urinary albumin creatinine ratio (mg/g Cr)‡	18	24.0 (0.0–75.0)			20	18.0 (12.0–61.0)			
CVR-R (%)	18	2.24±1.21			20	2.22±0.98			
CVR-R less than 2%, n (%)	18	8 (44.4)			20	10 (50.0)			
Combination therapy (SU/Gli/BG/TZD/αGII)	18	2/0/4/3/1			20	5/1/5/1/4			
HbA1c (%)	18	10.3±2.4			20	9.7±1.7			
HbA1c (mmol/mol)	18	88.7±25.9			20	83.1±18.5			
Fasting plasma glucose (mg/dL)	18	177.4±49.7			20	176.4±34.0			
Fasting plasma insulin (μIU/mL)	18	8.3±4.7			20	6.0±4.0			
HOMA-IR	18	3.52±2.00			20	2.57±1.81			
HOMA-β	18	30.5±18.5			20	21.2±14.4			
M-value	18	53.7±48.5	10.7±7.1	<0.001	20	41.1±32.6	22.8±25.0	<0.001	0.006
Mean blood glucose (mg/dL)	18	244.8±82.2	135.0±21.8	<0.001	20	230.5±55.1	174.6±52.2	<0.001	0.001
SD of blood glucose	18	57.3±0.5	41.5±16.3	0.011	20	57.4±17.9	52.8±21.8	0.252	0.058
Body mass index (kg/m²)	18	26.8±5.6	26.5±5.3	0.075	20	25.1±4.9	24.5±4.9	<0.001	0.045
White cell count (×10⁹/L)	18	6.06±1.85	5.26±1.77	0.001	20	6.51±1.82	6.09±1.76	0.094	0.145
Neutrophil count (×10⁹/L)	18	3.66±1.52	2.94±1.48	0.001	20	3.77±1.22	3.38±1.07	0.023	0.128
Aspartate aminotransferase (IU/L)	18	31.8±15.5	29.1±10.5	0.477	20	27.3±16.8	22.5±8.6	0.042	0.033
Alanine aminotransferase (IU/L)	18	46.4±27.2	39.4±17.2	0.118	20	41.9±39.5	34.6±19.7	0.411	0.412
γ-glutamyl transferase (IU/L)	18	74.9±76.4	49.6±53.5	0.002	20	67.8±86.8	44.5±49.5	<0.001	0.870
Total cholesterol (mg/dL)	18	181.4±45.4	169.6±35.7	0.166	20	186.8±34.9	172.0±43.1	0.015	0.875
Triglycerides (mg/dL)	18	163.2±145.8	122.8±62.9	0.072	20	156.4±62.9	126.9±55.4	0.007	0.706
HDL cholesterol (mg/dL)	18	44.9±13.0	45.2±13.5	0.864	20	42.7±12.7	39.4±11.2	0.016	0.034
LDL cholesterol (mg/dL)	18	103.9±33.1	99.9±26.7	<0.001	20	112.8±32.4	107.2±36.5	<0.001	0.978
Basal energy expenditure (kcal/day)	15	1464.1±438.8	1460.3±461.2	0.776	17	1465.4±262.3	1438.3±323.1	0.193	0.788
Respiratory quotient	15	0.92±0.22	0.89±0.11	0.975	17	0.94±0.23	1.00±0.29	0.011	0.075
Flow-mediated dilation (%)	14	5.84±2.69	6.93±6.45	0.507	15	5.00±3.06	5.55±2.48	0.453	0.620
24-hour low-frequency power (ms²)	13	5.23±0.85	4.26±0.40	0.003	13	5.53±1.08	4.24±0.22	0.003	0.698
24-hour high-frequency power (ms²)	13	4.28±0.90	3.49±0.35	0.009	13	4.53±0.83	3.25±0.33	<0.001	0.081
24-hour low-frequency to high-frequency power ratio	13	3.18±1.45	2.76±1.47	0.136	13	3.52±1.37	3.23±1.11	0.311	0.493

Continued

Table 1 Continued

Variable	Insulin aspart			Insulin detemir		
	n	Baseline	Endpoint	n	Baseline	Endpoint
Hypoglycemic event, n (%)	18		3 (16.7)	20		1 (5.0)
Insulin dose (unit)	18		35.9±17.4	20		16.0±8.4
Insulin dose (unit/kg)	18		0.55±0.31	20		0.23±0.11

Data are presented as mean±SD, unless otherwise specified.

*P value for intragroup comparison (baseline vs endpoint).

†P value for intergroup comparison (change from baseline between groups).

‡Data are presented as median (IQR).

BG, biguanide; CVR-R, coefficient of variation for R-R interval at rest; αGI, α-glucosidase inhibitor; Gli, glinide; HDL, high-density lipoprotein; HOMA-β, homeostatic model assessment β-cell function; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; SU, sulfonylurea; TZD, thiazolidinedione.

Metabolic profile and energy metabolism

Body mass index and serum levels of aspartate aminotransferase, triglycerides, total cholesterol, and high-density lipoprotein (HDL) cholesterol decreased only in the insulin detemir group (table 1), whereas neutrophil count, γ-glutamyltransferase, and LDL cholesterol showed a similar decrease in both groups. Morning basal energy expenditure and respiratory quotient were assessed in 15 and 17 patients in the insulin aspart and insulin detemir groups, respectively. The basal energy expenditure did not change even after the 2-week treatment in both groups. After treatment, the respiratory quotient significantly increased in the insulin detemir group but not in the insulin aspart group.

Treatment safety

Hypoglycemic events (blood glucose levels <70 mg/dL) were observed in three and one subject in the insulin aspart and insulin detemir groups, respectively (table 1). Hypoglycemic events occurred at prelude, postlude, or at bedtime in the insulin aspart group but only at prebreakfast in the insulin detemir group; these events did not occur just before or during the examination of endothelial function or cardiac autonomic nerve function. None of the hypoglycemic events were severe and all were immediately reversed with oral carbohydrate intake.

Total insulin dose

Total insulin dose at endpoint in the insulin aspart group was significantly greater than that in the insulin detemir group (table 1). Moreover, the total insulin dose tended to positively affect changes in body mass index in the insulin aspart group (r=0.457; p=0.056) but not in the insulin detemir group (r=0.008; p=0.972). Correlation between the total insulin dose at endpoint and baseline characteristics was then investigated in each group (online supplementary table 1). The total insulin dose at endpoint showed a positive correlation with the baseline hemoglobin A1c level (r=0.528; p=0.024), fasting plasma glucose level (r=0.637; p=0.004), white cell count (r=0.492; p=0.038), and neutrophil count (r=0.620; p=0.006) in the insulin aspart group, and with the baseline fasting plasma insulin level (r=0.530; p=0.016), HOMA-IR (r=0.510; p=0.022), and HOMA-β (r=0.481; p=0.032) in the insulin detemir group.

DISCUSSION

The present study indicated that both insulin aspart and insulin detemir significantly decreased the M-values and MBG levels. Insulin aspart prominently decreased the postprandial blood glucose levels, particularly after lunch and dinner and at bedtime, whereas insulin detemir decreased prandial and postprandial blood glucose levels almost uniformly. Reduction in the SD of blood glucose levels was thought to be caused by insulin aspart and not by insulin detemir treatment. Notably, equivalent nadir fasting blood glucose levels were observed after mealtime dosing of insulin aspart and bedtime dosing of insulin

Figure 1 The seven-point blood glucose profile at baseline and endpoint in the insulin aspart group (A) and insulin detemir group (B). The seven-point blood glucose profile at endpoint in the insulin aspart and insulin detemir groups (C). Data are expressed as mean $\pm$ SD. * $P < 0.05$ for comparisons between baseline and endpoint. † $P < 0.05$ for comparisons between the insulin aspart and insulin detemir groups.

Figure 2 Diurnal variations in low-frequency power at baseline and endpoint in the insulin aspart group (A) and insulin detemir group (B). Diurnal variations in high-frequency power at baseline and endpoint in the insulin aspart group (C) and insulin detemir group (D). Diurnal variations in low-frequency to high-frequency power ratio at baseline and endpoint in the insulin aspart group (E) and insulin detemir group (F). Data are expressed as mean $\pm$ SD. *P<0.05 for comparisons between baseline and endpoint.

detemir. This finding is consistent with that of our previous study wherein mealtime dosing of a rapid-acting insulin analog was shown to achieve adequate nadir fasting plasma glucose levels in approximately half of the study population comprising Japanese patients with type 2 diabetes.⁵ In the aforementioned study, impaired insulin secretion and excessive glucagon secretion affected the nadir fasting plasma glucose levels after mealtime dosing of the rapid-acting insulin analog. In addition, patients with type 2 diabetes who had longer disease duration and inadequate control with sulfonylureas did not achieve adequate nadir fasting plasma glucose levels. Indeed,

in the present study, only seven subjects used sulfonylureas (18.4%) at baseline. Consistent with the findings of the 4-T and APOLLO (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantus once daily or Lispro at mealtime in type 2 diabetes patients failing Oral treatment) studies,^{2,3} insulin aspart treatment required higher insulin doses to achieve fasting blood glucose levels comparable with those achieved with insulin detemir. In addition, the final insulin doses in the insulin detemir group were roughly half of those in the insulin aspart group, whereas these were almost similar in the 4-T and APOLLO studies.^{2,3} These findings

support the possibility that Japanese patients with type 2 diabetes, representing East Asians, require lower doses of long-acting insulin analogs to suppress hepatic glucose production than Caucasian patients with type 2 diabetes.

Short-term intravenous insulin infusion using a hyperinsulinemic-euglycemic clamp was shown to shift the cardiac autonomic nerve balance toward a sympathetic dominant state.^{17,18} However, the effects of chronic insulin treatment with either rapid-acting or long-acting insulin analogs on cardiac autonomic nerve function have remained unclear. Unexpectedly, the present study indicated that 2 weeks of insulin aspart treatment, but not insulin detemir treatment, shifted the daytime cardiac autonomic nerve balance toward a parasympathetic-dominant state. This finding is even more surprising considering the higher total insulin dose requirement in the insulin aspart group. A previous report showed that glycemic variability positively affects the cardiac sympathetic nerve activity.⁶ Therefore, chronic treatment with a rapid-acting insulin analog may suppress cardiac sympathetic nerve activity at least partially via correction of glycemic variability.

In the present study, each insulin regimen had its unique effect on the metabolic profile and energy metabolism. As observed in the 4-T and APOLLO studies,^{2,3} both insulin regimens exerted beneficial metabolic effects on the serum levels of γ -glutamyltransferase, triglycerides, and LDL cholesterol. Moreover, we observed a reduction in body mass index only in the insulin detemir group; this finding is consistent with the results of the 4-T and APOLLO studies wherein daily dosing of a long-acting insulin analog was less likely to result in body weight gain than mealtime dosing of a rapid-acting insulin analog.^{2,3} Similar to the 4-T study, the present study found a decrease in HDL cholesterol in the insulin detemir group but not in the insulin aspart group.

Bedtime insulin detemir treatment and not mealtime insulin aspart treatment increased the morning respiratory quotient. Insulin shifts the energy balance from a catabolic to an anabolic state by switching substrate oxidation from lipids to carbohydrates. Our findings corroborate those of a previous study wherein treatment with a long-acting insulin analog increased the morning respiratory quotient in subjects with type 2 diabetes.¹⁹ However, mealtime insulin aspart may have possibly increased the postprandial respiratory quotient.

Patients with type 2 diabetes have higher basal energy expenditure compared with individuals without diabetes.^{20–22} One of the physiologic mechanisms therein includes increased energy consumption due to hepatic gluconeogenesis. Given that treatment with a long-acting insulin analog effectively suppresses hepatic glucose production, it can be presumed to also decrease the basal energy expenditure. Indeed, previous studies have shown that bedtime insulin detemir treatment for 2²³ or 4 days¹⁸ decreases the basal energy expenditure. However, in the present study, 2 weeks of bedtime insulin detemir treatment did not change the morning basal

energy expenditure, a result that seemingly conflicts with those of previous reports. Further studies are therefore warranted to clarify the time-course changes in basal energy expenditure during insulin treatment.

CONCLUSION

Mealtime dosing of rapid-acting insulin aspart reduced glucose variability to a greater extent and achieved similar nadir fasting blood glucose levels compared with bedtime dosing of long-acting insulin detemir in patients with type 2 diabetes. Despite the need for higher insulin doses, rapid-acting insulin aspart reduced daytime cardiac sympathetic nerve activity. These properties may subsequently help reduce cardiovascular risks. The present study sheds light on the previously under-recognized properties of mealtime rapid-acting insulin dosing and may trigger reconsideration of patient-centered insulin therapy.

Author affiliations

¹Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

²Department of System Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

Presented at

Parts of this study were presented in abstract form at the 4th Scientific Meeting of the Asian Association for the Study of Diabetes, Kyoto, Japan, November 24–27, 2012 (PCS-16-5).

Contributors TK and TT contributed to the study design, data collection, data analysis, and data interpretation, and drafted the manuscript. YT contributed to the study design and data collection. YI, KK, and HM contributed to the data collection. SK contributed to the study design and data interpretation. TT is the guarantor of this work, and as such had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Obtained.

Ethics approval This study was approved by the Ethics Committee of the Kanazawa University Hospital, Ishikawa, Japan, and was conducted in accordance with the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: *Standards of Medical Care in Diabetes-2018*. *Diabetes Care* 2018;41(Suppl 1):S73–S85.
- Holman RR, Thorne KI, Farmer AJ, *et al*. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *N Engl J Med* 2007;357:1716–30.
- Bretzel RG, Nuber U, Landgraf W, *et al*. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *Lancet* 2008;371:1073–84.

4. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. *Diabetes Res Clin Pract* 2004;66 Suppl 1:S37–S43.
5. Takamura T, Sakurai M, Nakamura M, *et al.* Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. *Diabetes Res Clin Pract* 2007;75:278–84.
6. Di Flaviani A, Picconi F, Di Stefano P, *et al.* Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. *Diabetes Care* 2011;34:1605–9.
7. Buscemi S, Re A, Batsis JA, *et al.* Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. *Diabet Med* 2010;27:872–8.
8. Seino Y, Nanjo K, Tajima N, *et al.* Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *Diabetol Int* 2010;1:2–20.
9. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar control in diabetics. *Acta Med Scand* 1965;177:95–102.
10. Wójcicki JM. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull "M"-value. *Horm Metab Res* 1995;27:1–5.
11. Matthews DR, Hosker JP, Rudenski AS, *et al.* Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–9.
12. Kageyama S, Taniguchi I, Tanaka S, *et al.* A critical level of diabetic autonomic neuropathy. *Tohoku J Exp Med* 1983;141(Suppl):479–83.
13. Corretti MC, Anderson TJ, Benjamin EJ, *et al.* Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 2002;39:257–65.
14. Thijssen DH, Black MA, Pyke KE, *et al.* Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. *Am J Physiol Heart Circ Physiol* 2011;300:H2–H12.
15. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Eur Heart J* 1996;17:354–81.
16. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. *J Physiol* 1949;109:1–9.
17. Bellavere F, Cacciatori V, Moghetti P, *et al.* Acute effect of insulin on autonomic regulation of the cardiovascular system: a study by heart rate spectral analysis. *Diabet Med* 1996;13:709–14.
18. Paolisso G, Manzella D, Tagliamonte MR, *et al.* Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. *Metabolism* 1999;48:755–62.
19. Gonzalez C, Fagour C, Maury E, *et al.* Early changes in respiratory quotient and resting energy expenditure predict later weight changes in patients treated for poorly controlled type 2 diabetes. *Diabetes Metab* 2014;40:299–304.
20. Fontvieille AM, Lillioja S, Ferraro RT, *et al.* Twenty-four-hour energy expenditure in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1992;35:753–9.
21. Bitz C, Toubro S, Larsen TM, *et al.* Increased 24-h energy expenditure in type 2 diabetes. *Diabetes Care* 2004;27:2416–21.
22. Miyake R, Ohkawara K, Ishikawa-Takata K, *et al.* Obese Japanese adults with type 2 diabetes have higher basal metabolic rates than non-diabetic adults. *J Nutr Sci Vitaminol* 2011;57:348–54.
23. Fagour C, Gonzalez C, Suberville C, *et al.* Early decrease in resting energy expenditure with bedtime insulin therapy. *Diabetes Metab* 2009;35:332–5.